Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL14698371 | 1.00 | DPP4 (0.81) | DPP4CHRM1 | |
| Water SCHEMBL14698370 | 1.00 | DPP4 (0.81) | DPP4CHRM1 | |
| SCHEMBL196623 | 1.00 | DPP4 (0.81) | DPP4CHRM1 | |
| SCHEMBL497393 | 1.00 | DPP4 (0.81) | DPP4CHRM1 | |
| Hydrochloric Acid SCHEMBL497609 | 0.99 | DPP4 (0.80) | DPP4CHRM1 | |
| Hydrochloric Acid SCHEMBL497580 | 0.99 | DPP4 (0.80) | DPP4CHRM1 | |
| Hydrochloric Acid SCHEMBL497712 | 0.99 | DPP4 (0.80) | DPP4CHRM1 | |
| Hydrochloric Acid SCHEMBL15049683 | 0.99 | DPP4 (0.80) | DPP4CHRM1 | |
| SCHEMBL8270380 | 0.93 | DPP4 (0.69) | DPP4CHRM1 | |
| SCHEMBL9910543 | 0.92 | DPP4 (0.69) | DPP4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2025-10-09 | — | — | US | claimed |
| EP-4234012-A2 | SGLT2 INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2023-08-30 | — | — | EP | claimed |
| EP-3485890-B1 | SGLT2 INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-05-10 | — | — | EP | claimed |
| US-20220323434-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2022-10-13 | — | — | US | claimed |
| EP-3939577-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2022-01-19 | — | — | EP | claimed |
| CN-112656945-A | Treatment of diabetes in patients unsuited for metformin therapy | 勃林格殷格翰国际有限公司 | 2021-04-16 | — | — | CN | claimed |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2021-04-01 | — | — | US | claimed |
| EP-3626238-A1 | DPP-4 INHIBITORS FOR USE FOR THE TREATMENT OF WOUND HEALING IN DIABETIC PATIENTS | Boehringer Ingelheim International GmbH (DE) | 2020-03-25 | — | — | EP | claimed |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2019-04-11 | — | — | US | claimed |
| EP-3348263-A1 | DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD | Boehringer Ingelheim International GmbH (DE) | 2018-07-18 | — | — | EP | claimed |
| WO-2010043688-A1 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | WO | claimed |
| WO-2010029089-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-18 | — | — | WO | claimed |
| WO-2010018217-A2 | ORGANIC COMPOUNDS FOR WOUND HEALING | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | WO | claimed |
| WO-2010015664-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | WO | claimed |
| WO-2009147125-A1 | DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | WO | claimed |
| EP-1758905-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2009-04-29 | — | — | EP | claimed |
| US-7501426-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-10 | — | — | US | claimed |
| WO-2009022007-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| WO-2009022008-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| WO-2009022010-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 4038/4885 |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 4038/4885 |
| US-20220323434-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 4038/4885 |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.